La selección de la terapia sistémica de primera línea para el carcinoma de vesícula biliar avanzado o metastásico requiere una consideración cuidadosa del estado funcional. Los pacientes con un estado funcional ECOG de 2 — u otros factores de fragilidad — representan un subgrupo específico para quienes el enfoque terapéutico difiere del de aquellos con mejor estado funcional.
DOI: 10.1016/j.annonc.2022.10.506
Gemcitabine monotherapy may be used in patients with a PS of 2.
Gemcitabine monotherapy may be preferred in patients with a PS of 2 or other factors of fragility.
During systemic and locoregional therapy for advanced disease, follow-up should be conducted at a frequency of 8-12 weeks to allow best assessment of treatment efficacy, or as required for disease-related complications.
In addition to imaging by CT or MRI, CA 19-9 or carcinoembryonic antigen (CEA) levels may be used to monitor the course of the disease if one or both are known to be secreted.
View source ↗